MCID: TCL005
MIFTS: 52

T-Cell Prolymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

MalaCards integrated aliases for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 54 60 30 6 17 74
T-Cell Chronic Lymphocytic Leukemia 60
Lymphocytic Leukemia T-Cell Chronic 56
T Cell Prolymphocytic Leukemia 54
Leukemia, T-Cell, Chronic 74
T-Pll 60

Characteristics:

Orphanet epidemiological data:

60
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

ICD10 34 C91.6
MESH via Orphanet 46 D015461
ICD10 via Orphanet 35 C91.6
UMLS via Orphanet 75 C0023494 C2363142
Orphanet 60 ORPHA86871

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to prolymphocytic leukemia and precursor t-cell acute lymphoblastic leukemia. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Human cytomegalovirus infection and TCR Signaling (Qiagen). The drugs Cyclophosphamide and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 prolymphocytic leukemia 33.0 ATM MTCP1 MYC TCL1A
2 precursor t-cell acute lymphoblastic leukemia 29.8 ABL1 CD7 MYC TCL1A
3 leukemia, chronic lymphocytic 29.6 ATM CD52 MS4A1 TCL1A
4 t-cell leukemia 29.2 ATM CD7 JAK3 MYC NFKB1 TCL1A
5 leukemia 11.2
6 lymphoma 10.5
7 lymphocytic leukemia 10.3
8 t-cell lymphoma 1a 10.3
9 leukemia, chronic lymphocytic 2 10.2
10 kaposi sarcoma 10.2
11 ataxia-telangiectasia 10.2
12 diffuse large b-cell lymphoma 10.2
13 sarcoma 10.2
14 leukemia, b-cell, chronic 10.2
15 lymphoblastic leukemia, acute, with lymphomatous features 10.2 ABL1 JAK1 JAK3
16 pure red-cell aplasia 10.1
17 jak3-deficient severe combined immunodeficiency 10.1 JAK1 JAK3
18 breast cancer 10.1
19 prostate cancer 10.1
20 nijmegen breakage syndrome 10.1
21 ataxia and polyneuropathy, adult-onset 10.1
22 prostate cancer, hereditary, 8 10.1
23 prostate cancer, hereditary, 6 10.1
24 gastric cancer 10.1
25 infantile liver failure syndrome 1 10.1
26 autoimmune lymphoproliferative syndrome, type v 10.1
27 acute liver failure 10.1
28 peripheral t-cell lymphoma 10.1
29 t-cell large granular lymphocyte leukemia 10.1
30 lymphoproliferative syndrome 10.1
31 panuveitis 10.1
32 telangiectasis 10.1
33 guillain-barre syndrome 10.1
34 scleritis 10.1
35 anterior scleritis 10.1
36 purpura 10.1
37 palmoplantar keratosis 10.1
38 retinitis 10.1
39 vasculitis 10.1
40 leishmaniasis 10.1
41 visceral leishmaniasis 10.1
42 large granular lymphocyte leukemia 10.1
43 xp22.3 microdeletion syndrome 10.1
44 hematopoietic stem cell transplantation 10.1
45 polycythemia vera 10.0 ABL1 JAK1 JAK3
46 lactocele 10.0 JAK1 JAK3
47 pityriasis lichenoides 10.0 CD7 MS4A1
48 thymoma, familial 10.0
49 pemphigus foliaceus 10.0
50 erythema multiforme 10.0

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

27 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.35 ABL1 MYC SMARCB1
2 Decreased viability GR00221-A-2 10.35 ABL1 CHEK2 SMARCB1
3 Decreased viability GR00221-A-3 10.35 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
4 Decreased viability GR00221-A-4 10.35 ATM CHEK2
5 Decreased viability GR00342-S-1 10.35 ABL1
6 Decreased viability GR00342-S-2 10.35 ABL1 CHEK2
7 Decreased viability GR00342-S-3 10.35 ABL1
8 Decreased viability GR00381-A-1 10.35 SMARCB1
9 Decreased viability GR00402-S-2 10.35 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.33 ABL1 SMARCB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.33 ABL1 ATM JAK3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.33 ATM JAK3 SMARCB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.33 ATM CHEK2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.33 CHEK2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.33 ATM SMARCB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.33 ABL1 CHEK2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.33 ATM JAK3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.33 ABL1 ATM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.33 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.33 ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.33 ATM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.33 SMARCB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.33 SMARCB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.33 JAK3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.33 CHEK2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.33 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.33 ATM
28 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.33 ABL1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.33 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.33 ATM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.33 ABL1 JAK3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.33 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.33 JAK3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.33 ABL1 ATM
35 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.33 ATM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.33 ATM
37 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.33 ABL1 SMARCB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.33 ABL1 ATM CHEK2 JAK3 SMARCB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.33 JAK3
40 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.72 ABL1 ATM CHEK2 JAK1 JAK3
41 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.54 ATM CDKN1B JAK1
42 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.17 ABL1 ATM BRCC3 C11orf65 CDKN1B CHEK2
43 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK1 JAK3

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 ABL1 ATM CDKN1B CHEK2 JAK3 MYC
2 hematopoietic system MP:0005397 10.03 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
3 endocrine/exocrine gland MP:0005379 10.02 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
4 immune system MP:0005387 9.97 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
5 digestive/alimentary MP:0005381 9.91 ABL1 CDKN1B JAK3 MYC NFKB1 SMARCB1
6 liver/biliary system MP:0005370 9.5 ABL1 CDKN1B JAK1 MYC NFKB1 SMARCB1
7 neoplasm MP:0002006 9.1 ATM CDKN1B CHEK2 MYC SMARCB1 VEGFA

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Fludarabine Approved Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
3
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0
4
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
5
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
6
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
7
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
8
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
9
Cytarabine Approved, Experimental, Investigational Phase 2,Phase 1 147-94-4, 65-46-3 6253
10
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
11
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
12
Melphalan Approved Phase 2,Phase 1 148-82-3 460612 4053
13
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
14
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
15
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
16
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
17
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
18
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
19
Emodepside Investigational, Vet_approved Phase 2,Phase 1 155030-63-0
20 Antineoplastic Agents, Alkylating Phase 2,Phase 1
21 Antineoplastic Agents, Immunological Phase 2,Phase 1
22 Antimetabolites Phase 2,Phase 1
23 Antirheumatic Agents Phase 2,Phase 1
24 Topoisomerase Inhibitors Phase 2,Phase 1
25 Immunologic Factors Phase 2,Phase 1
26 Analgesics Phase 2
27 Antiviral Agents Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 2
29 Anti-Infective Agents Phase 2,Phase 1
30 Alkylating Agents Phase 2,Phase 1
31 Immunosuppressive Agents Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 2,Phase 1
33 Vidarabine Phosphate Phase 2,Phase 1
34 Antimitotic Agents Phase 2,Phase 1
35 Antibiotics, Antitubercular Phase 2,Phase 1
36 Keratolytic Agents Phase 2,Phase 1
37 Antitubercular Agents Phase 2,Phase 1
38 Podophyllotoxin Phase 2,Phase 1 518-28-5
39 Dermatologic Agents Phase 2,Phase 1
40 alanine Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 2,Phase 1
42 Etoposide phosphate Phase 2,Phase 1
43 phenylalanine Phase 2,Phase 1
44 Nitrogen Mustard Compounds Phase 2,Phase 1
45 Calcineurin Inhibitors Phase 2,Phase 1
46 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
47 Antifungal Agents Phase 2,Phase 1
48 Cyclosporins Phase 2,Phase 1
49
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
50
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
2 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
3 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
4 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
5 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
6 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Active, not recruiting NCT00005803 Phase 1, Phase 2 Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
7 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia Not yet recruiting NCT03873493 Phase 2 Venetoclax;Ibrutinib
8 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia Terminated NCT00413478 Phase 2 5-Azacytidine
9 Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Withdrawn NCT01162031 Phase 2 Velcade
10 A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) Completed NCT00749502 Phase 1 MK-4827
11 Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) Completed NCT00124189 Phase 1 GRN163L
12 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Completed NCT01094860 Phase 1 Nelarabine
13 Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting NCT02576496 Phase 1 EDO-S101
14 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Recruiting NCT02512497 Phase 1 Romidepsin;Busulfan;Fludarabine;Thymoglobulin
15 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
16 Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
17 Registry of the German CLL Study Group Recruiting NCT02863692

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 30

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

42
T Cells, Bone Marrow, Skin, Spleen, Lymph Node, B Cells, Eye

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 217)
# Title Authors Year
1
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. ( 30997845 )
2019
2
Where do we currently stand with T-cell prolymphocytic leukemia? ( 30668215 )
2019
3
Papuloerythroderma-like cutaneous involvement of a CD62L- subclone of T-cell prolymphocytic leukemia. ( 30450688 )
2019
4
Concomitant T-cell prolymphocytic leukemia and visceral leishmaniasis: A case report. ( 30235714 )
2018
5
Small cell variant of T-cell prolymphocytic leukemia with atypical presentation. ( 30588459 )
2018
6
Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. ( 30414304 )
2018
7
T-Cell Prolymphocytic Leukemia: An Experience from a Tertiary Cancer Centre in South India. ( 30233775 )
2018
8
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2018
9
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
10
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
11
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. ( 29483097 )
2018
12
Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis. ( 29928415 )
2018
13
T-cell prolymphocytic leukemia negative for surface CD3 and CD45. ( 29976781 )
2018
14
T Cell Prolymphocytic Leukemia (T-PLL): Cutaneous Involvement in an Uncommon Leukemia. ( 30127581 )
2018
15
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
16
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
17
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
18
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
19
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
20
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
21
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
22
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
23
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
24
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
25
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
26
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
27
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
28
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
29
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2016
30
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2016
31
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
32
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
33
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
34
Encephalitozoon hellem in a patient with CD4+ T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
35
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
36
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
37
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
38
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
39
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
40
Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL). ( 25888568 )
2015
41
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
42
Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. ( 24977988 )
2014
43
T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities. ( 25238936 )
2014
44
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
45
Coronary vasculitis associated with T-cell prolymphocytic leukemia. ( 23731632 )
2014
46
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. ( 24048415 )
2014
47
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. ( 24446122 )
2014
48
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014
49
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
50
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. ( 24825865 )
2014

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh38 Chromosome 11, 108301779: 108301779
2 ATM NM_000051.3(ATM): c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del) deletion Conflicting interpretations of pathogenicity rs587776547 GRCh38 Chromosome 11, 108331887: 108331895
3 ATM NM_000051.3(ATM): c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del) deletion Conflicting interpretations of pathogenicity rs587776547 GRCh37 Chromosome 11, 108202614: 108202622
4 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh37 Chromosome 11, 108199929: 108199929
5 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh38 Chromosome 11, 108329202: 108329202
6 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh37 Chromosome 11, 108170479: 108170479
7 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh38 Chromosome 11, 108299752: 108299752
8 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh37 Chromosome 11, 108172506: 108172506

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
7 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
8 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
9 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
10 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
11 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
12 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
13 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
14 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
15 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
16 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
17 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
18 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
19 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
20 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
21 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
22 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
23 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
24 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
25 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
26 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
27 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
28 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
29 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
30 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
31 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
32 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
33 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
34 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
35 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
36 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
37 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
38 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
39 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
40 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
41 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
42 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
43 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
44 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 ATM CDKN1B JAK1 MYC NFKB1 SAMHD1
2
Show member pathways
12.9 ATM CHEK2 JAK1 JAK3 NFKB1
3
Show member pathways
12.86 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
4 12.8 ABL1 CDKN1B JAK1 JAK3 MYC NFKB1
5
Show member pathways
12.77 CDKN1B JAK1 JAK3 MYC NFKB1
6
Show member pathways
12.68 ATM CDKN1B JAK1 JAK3 VEGFA
7
Show member pathways
12.64 ATM CDKN1B JAK1 JAK3 MTCP1 MYC
8
Show member pathways
12.51 CDKN1B JAK1 MYC NFKB1
9 12.49 ATM BRCC3 CDKN1B CHEK2
10
Show member pathways
12.49 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
11 12.46 ABL1 ATM CDKN1B MYC NFKB1 VEGFA
12
Show member pathways
12.39 JAK1 JAK3 NFKB1 VEGFA
13
Show member pathways
12.39 CDKN1B JAK1 JAK3 MYC NFKB1
14
Show member pathways
12.38 ABL1 JAK1 JAK3 MYC
15
Show member pathways
12.36 ABL1 ATM BRCC3 CHEK2
16
Show member pathways
12.36 ABL1 ATM CDKN1B CHEK2 MYC
17 12.33 ABL1 ATM CDKN1B CHEK2 MYC
18 12.29 CDKN1B JAK1 JAK3 NFKB1
19
Show member pathways
12.25 ABL1 ATM JAK1 MYC SAMHD1
20 12.24 ATM CDKN1B MYC NFKB1
21
Show member pathways
12.22 CDKN1B JAK1 JAK3 NFKB1 VEGFA
22
Show member pathways
12.21 CDKN1B CHEK2 MYC NFKB1
23 12.19 ATM CHEK2 JAK1 JAK3 MYC NFKB1
24 12.18 JAK1 MYC NFKB1 VEGFA
25 12.16 ATM CHEK2 MYC NFKB1
26 11.97 JAK1 JAK3 MYC VEGFA
27
Show member pathways
11.95 JAK1 JAK3 MYC NFKB1
28 11.89 CDKN1B NFKB1 VEGFA
29 11.89 CDKN1B NFKB1 VEGFA
30
Show member pathways
11.86 JAK1 JAK3 NFKB1
31 11.85 CDKN1B MYC NFKB1
32 11.83 ABL1 CDKN1B MYC
33
Show member pathways
11.82 ABL1 ATM CHEK2
34
Show member pathways
11.8 ATM CHEK2 SMARCB1
35 11.78 ABL1 ATM CDKN1B MYC NFKB1
36 11.73 ATM CDKN1B MYC
37 11.7 CDKN1B JAK1 MYC
38 11.68 ATM CHEK2 MYC
39
Show member pathways
11.67 JAK1 JAK3 MYC NFKB1
40 11.63 ABL1 ATM CHEK2
41
Show member pathways
11.61 CDKN1B JAK1 MYC NFKB1
42 11.6 ABL1 CDKN1B SMARCB1
44 11.53 JAK1 MYC NFKB1 VEGFA
45 11.51 JAK1 MYC NFKB1
46 11.49 ATM CHEK2 NFKB1
47 11.49 ABL1 ATM CDKN1B MYC
48 11.47 ABL1 ATM CDKN1B MYC NFKB1
49 11.46 CDKN1B MYC NFKB1 VEGFA
50
Show member pathways
11.45 JAK1 JAK3 VEGFA

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.1 ABL1 CDKN1B MTCP1 MYC SMARCB1 TCL1A

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 ABL1 ATM CHEK2 JAK1 JAK3
2 cell cycle GO:0007049 9.98 ATM BRCC3 CDKN1B CHEK2 SMARCB1
3 negative regulation of apoptotic process GO:0043066 9.97 CDKN1B MYC NFKB1 TCL1A VEGFA
4 cytokine-mediated signaling pathway GO:0019221 9.88 JAK1 JAK3 MYC VEGFA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 MTCP1 TCL1A VEGFA
6 DNA repair GO:0006281 9.65 ABL1 ATM BRCC3 CHEK2 SAMHD1
7 interleukin-15-mediated signaling pathway GO:0035723 9.56 JAK1 JAK3
8 replicative senescence GO:0090399 9.55 ATM CHEK2
9 cellular response to angiotensin GO:1904385 9.54 MYC NFKB1
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.54 ATM CDKN1B CHEK2
11 positive regulation of response to DNA damage stimulus GO:2001022 9.52 ATM MYC
12 signal transduction in response to DNA damage GO:0042770 9.51 ABL1 CHEK2
13 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.5 ABL1 ATM CHEK2
14 interleukin-2-mediated signaling pathway GO:0038110 9.48 JAK1 JAK3
15 positive regulation of mitochondrial membrane potential GO:0010918 9.46 MYC TCL1A
16 cell cycle arrest GO:0007050 9.46 ABL1 ATM CDKN1B MYC
17 interleukin-9-mediated signaling pathway GO:0038113 9.43 JAK1 JAK3
18 cellular response to DNA damage stimulus GO:0006974 9.43 ABL1 ATM BRCC3 CHEK2 MYC SAMHD1
19 interleukin-21-mediated signaling pathway GO:0038114 9.4 JAK1 JAK3
20 DNA damage induced protein phosphorylation GO:0006975 8.8 ABL1 ATM CHEK2

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 CDKN1B JAK1 JAK3
2 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.8 ABL1 JAK1 JAK3

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....